Monday, December 23, 2024
HomeTagsRefractory Hodgkin

Refractory Hodgkin

ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

ADC Therapeutics SA announced results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma....
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics